# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
114, Journal, 0, 12, "Diabetologia", "", "<http://ctro/data#Publication_34511> <http://ctro/data#hasJournal> \"Diabetologia\"."
1, PublicationYear, 15, 19, "2012", "", "<http://ctro/data#Publication_34511> <http://ctro/data#hasPublicationYear> \"2012\"."
5, Title, 110, 288, "Effect of bile acid sequestrants on glucose metabolism , hepatic de novo lipogenesis , and cholesterol and bile acid kinetics in type 2 diabetes : a randomised controlled study .", "", "<http://ctro/data#Publication_34511> <http://ctro/data#hasTitle> \"Effect of bile acid sequestrants on glucose metabolism , hepatic de novo lipogenesis , and cholesterol and bile acid kinetics in type 2 diabetes : a randomised controlled study .\"."
3, Type2Diabetes, 239, 254, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_34518> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
4, Randomized, 259, 269, "randomised", "", "<http://ctro/data#ClinicalTrial_34518> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
6, Author, 289, 297, "Beysen C", "", "<http://ctro/data#Publication_34511> <http://ctro/data#hasAuthor> \"Beysen C\"."
7, Author, 306, 315, "Murphy EJ", "", "<http://ctro/data#Publication_34511> <http://ctro/data#hasAuthor> \"Murphy EJ\"."
8, Author, 318, 326, "Deines K", "", "<http://ctro/data#Publication_34511> <http://ctro/data#hasAuthor> \"Deines K\"."
9, Author, 329, 335, "Chan M", "", "<http://ctro/data#Publication_34511> <http://ctro/data#hasAuthor> \"Chan M\"."
10, Author, 338, 345, "Tsang E", "", "<http://ctro/data#Publication_34511> <http://ctro/data#hasAuthor> \"Tsang E\"."
11, Author, 348, 355, "Glass A", "", "<http://ctro/data#Publication_34511> <http://ctro/data#hasAuthor> \"Glass A\"."
12, Author, 358, 367, "Turner SM", "", "<http://ctro/data#Publication_34511> <http://ctro/data#hasAuthor> \"Turner SM\"."
13, Author, 370, 380, "Protasio J", "", "<http://ctro/data#Publication_34511> <http://ctro/data#hasAuthor> \"Protasio J\"."
14, Author, 383, 390, "Riiff T", "", "<http://ctro/data#Publication_34511> <http://ctro/data#hasAuthor> \"Riiff T\"."
15, Author, 393, 407, "Hellerstein MK", "", "<http://ctro/data#Publication_34511> <http://ctro/data#hasAuthor> \"Hellerstein MK\"."
16, USA, 510, 513, "USA", "", 
22, ObjectiveDescription, 619, 801, "The primary aim of this completed multicentre randomised , parallel , double - blind placebo - controlled study was to elucidate the mechanisms of glucose - lowering with colesevelam", "", "<http://ctro/data#ClinicalTrial_34518> <http://ctro/data#hasObjectiveDescription> \"The primary aim of this completed multicentre randomised , parallel , double - blind placebo - controlled study was to elucidate the mechanisms of glucose - lowering with colesevelam\"."
17, Multicenter, 653, 664, "multicentre", "", "<http://ctro/data#ClinicalTrial_34518> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
18, Randomized, 665, 675, "randomised", "", 
19, Parallel, 678, 686, "parallel", "", 
20, DoubleBlind, 689, 703, "double - blind", "", "<http://ctro/data#ClinicalTrial_34518> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
110, Placebo, 704, 711, "placebo", "", 
79764, Colesevelam, 790, 801, "colesevelam", "", 
23, ObjectiveDescription, 802, 936, "and secondarily to investigate its effects on lipid metabolism ( hepatic de novo lipogenesis , cholesterol and bile acid synthesis ) .", "", "<http://ctro/data#ClinicalTrial_34518> <http://ctro/data#hasObjectiveDescription> \"and secondarily to investigate its effects on lipid metabolism ( hepatic de novo lipogenesis , cholesterol and bile acid synthesis ) .\"."
61256, Precondition, 947, 980, "Participants with type 2 diabetes", "", "<http://ctro/data#Population_34534> <http://ctro/data#hasPrecondition> \"Participants with type 2 diabetes\"."
24, Type2Diabetes, 965, 980, "type 2 diabetes", "", 
137, HbA1c, 983, 993, "HbA ( 1c )", "", 
26, Percentage, 1009, 1010, "%", "", 
79759, Millimoles_per_mole, 1021, 1031, "mmol / mol", "", 
140, FastingBloodGlucose, 1036, 1051, "fasting glucose", "", 
29, Millimoles_per_litre, 1061, 1069, "mmol / l", "", 
30, EndPointDescription, 1072, 1096, "fasting triacylglycerols", "", 
32, Millimoles_per_litre, 1105, 1113, "mmol / l", "", 
147, Precondition, 1118, 1153, "LDL - cholesterol > 1 . 55 mmol / l", "", "<http://ctro/data#Population_34534> <http://ctro/data#hasPrecondition> \"LDL - cholesterol > 1 . 55 mmol / l\"."
31, EndPointDescription, 1118, 1135, "LDL - cholesterol", "", 
33, Millimoles_per_litre, 1145, 1153, "mmol / l", "", 
150, Precondition, 1156, 1238, "treated with diet and exercise , sulfonylurea , metformin or a combination thereof", "", "<http://ctro/data#Population_34534> <http://ctro/data#hasPrecondition> \"treated with diet and exercise , sulfonylurea , metformin or a combination thereof\"."
34, Sulfonylureas, 1189, 1201, "sulfonylurea", "", 
35, Metformin, 1204, 1213, "metformin", "", 
38, Randomized, 1246, 1256, "randomised", "", 
39, DoseValue, 1292, 1298, "3 . 75", "", "<http://ctro/data#Medication_34572> <http://ctro/data#hasDoseValue> \"3 . 75\"."
40, Gram, 1299, 1300, "g", "", "<http://ctro/data#Medication_34572> <http://ctro/data#hasDoseUnit> <http://ctro/data#Gram>."
41, Frequency, 1303, 1306, "day", "", "<http://ctro/data#Intervention_34560> <http://ctro/data#hasFrequency> \"day\"."
79765, Colesevelam, 1307, 1318, "colesevelam", "", "<http://ctro/data#Medication_34572> <http://ctro/data#hasDrug> <http://ctro/data#Colesevelam>."
43, NumberPatientsArm, 1325, 1327, "30", "", "<http://ctro/data#Arm_34542> <http://ctro/data#hasNumberPatientsArm> \"30\"."
45, Placebo, 1333, 1340, "placebo", "", "<http://ctro/data#Medication_34579> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
44, NumberPatientsArm, 1347, 1349, "30", "", "<http://ctro/data#Arm_34551> <http://ctro/data#hasNumberPatientsArm> \"30\"."
46, Duration, 1356, 1364, "12 weeks", "", "<http://ctro/data#ClinicalTrial_34518> <http://ctro/data#hasCTduration> \"12 weeks\"."
157, Multicenter, 1368, 1388, "three clinical sites", "", 
47, USA, 1396, 1399, "USA", "", 
162, TimePoint, 1442, 1450, "baseline", "", 
79762, Colesevelam, 1476, 1487, "colesevelam", "", 
49, Placebo, 1500, 1507, "placebo", "", 
61270, EndPointDescription, 1520, 1552, "Fasting and postprandial glucose", "", 
61271, EndPointDescription, 1555, 1560, "lipid", "", 
61272, EndPointDescription, 1565, 1583, "bile acid pathways", "", 
61271, EndPointDescription, 1575, 1583, "pathways", "", 
165, TimePoint, 1601, 1609, "baseline", "", 
166, TimePoint, 1614, 1630, "post - treatment", "", 
53, MeasurementDevice, 1644, 1662, "isotope techniques", "", 
61268, PlasmaGlucose, 1665, 1679, "Plasma glucose", "", 
61269, Insulin, 1682, 1689, "insulin", "", 
55, EndPointDescription, 1698, 1725, "glucagon - like peptide - 1", "", 
56, EndPointDescription, 1728, 1735, "GLP - 1", "", 
57, EndPointDescription, 1746, 1792, "glucose - dependent insulinotropic polypeptide", "", 
58, EndPointDescription, 1795, 1798, "GIP", "", 
59, EndPointDescription, 1803, 1845, "glucagon and fibroblast growth factor - 19", "", 
60, EndPointDescription, 1848, 1856, "FGF - 19", "", 
167, DoubleBlind, 1951, 2000, "Data was collected by people blinded to treatment", "", 
61, Placebo, 2027, 2034, "placebo", "", 
79768, Colesevelam, 2037, 2048, "colesevelam", "", 
73, ObservedResult, 2049, 2057, "improved", "", 
62, HbA1c, 2058, 2068, "HbA ( 1c )", "", "<http://ctro/data#Endpoint_34632> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
171, Mean, 2071, 2075, "mean", "", "<http://ctro/data#Mean_34634> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_34632> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_34634>."
172, TimePoint, 2088, 2096, "baseline", "", 
61267, Increment, 2100, 2105, "0 . 3", "", "<http://ctro/data#Outcome_34664> <http://ctro/data#hasChangeValue> \"0 . 3\"."
61264, SdDevChangeValue, 2111, 2116, "1 . 1", "", "<http://ctro/data#Outcome_34664> <http://ctro/data#hasSdDevChangeValue> \"1 . 1\"."
63, Percentage, 2119, 2120, "%", "", "<http://ctro/data#Endpoint_34632> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
212, Placebo, 2125, 2132, "placebo", "", 
65, FinalNumPatientsArm, 2139, 2141, "28", "", "<http://ctro/data#Arm_34551> <http://ctro/data#hasFinalNumPatientsArm> \"28\"."
69, Reduction, 2150, 2155, "0 . 3", "", "<http://ctro/data#Outcome_34637> <http://ctro/data#hasChangeValue> \"0 . 3\"."
68, SdDevChangeValue, 2158, 2163, "1 . 1", "", "<http://ctro/data#Outcome_34637> <http://ctro/data#hasSdDevChangeValue> \"1 . 1\"."
64, Percentage, 2166, 2167, "%", "", 
79767, Colesevelam, 2172, 2183, "colesevelam", "", 
71, FinalNumPatientsArm, 2190, 2192, "26", "", "<http://ctro/data#Arm_34542> <http://ctro/data#hasFinalNumPatientsArm> \"26\"."
74, EndPointDescription, 2199, 2221, "glucose concentrations", "", 
216, EndPointDescription, 2224, 2256, "fasting plasma glucose clearance", "", 
76, FastingPlasmaGlucose, 2224, 2246, "fasting plasma glucose", "", 
75, EndPointDescription, 2261, 2296, "glycolytic disposal of oral glucose", "", 
79772, Colesevelam, 2299, 2310, "Colesevelam", "", 
187, EndPointDescription, 2394, 2431, "Fasting endogenous glucose production", "", "<http://ctro/data#EndPointDescription_34692> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_34691> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_34692>."
82, EndPointDescription, 2436, 2450, "glycogenolysis", "", "<http://ctro/data#EndPointDescription_34697> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_34696> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_34697>."
189, ObservedResult, 2451, 2474, "significantly increased", "", "<http://ctro/data#Outcome_34701> <http://ctro/data#hasObservedResult> \"significantly increased\". <http://ctro/data#Outcome_34728> <http://ctro/data#hasObservedResult> \"significantly increased\"."
90, Placebo, 2480, 2487, "placebo", "", 
190, ObservedResult, 2497, 2506, "unchanged", "", 
79766, Colesevelam, 2512, 2523, "colesevelam", "", 
95, Placebo, 2600, 2607, "placebo", "", 
79769, Colesevelam, 2610, 2621, "colesevelam", "", 
96, ObservedResult, 2622, 2631, "increased", "", "<http://ctro/data#Outcome_34770> <http://ctro/data#hasObservedResult> \"increased\". <http://ctro/data#Outcome_34797> <http://ctro/data#hasObservedResult> \"increased\"."
83, EndPointDescription, 2638, 2645, "GLP - 1", "", "<http://ctro/data#EndPointDescription_34756> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_34755> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_34756>."
84, EndPointDescription, 2650, 2653, "GIP", "", 
97, ObservedResult, 2673, 2681, "improved", "", "<http://ctro/data#Outcome_34824> <http://ctro/data#hasObservedResult> \"improved\"."
85, EndPointDescription, 2682, 2707, "HOMA - beta cell function", "", "<http://ctro/data#EndPointDescription_34766> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_34765> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_34766>."
86, EndPointDescription, 2714, 2721, "insulin", "", 
87, EndPointDescription, 2724, 2732, "glucagon", "", 
88, EndPointDescription, 2737, 2762, "HOMA - insulin resistance", "", 
98, ObservedResult, 2763, 2777, "were unchanged", "", 
79770, Colesevelam, 2780, 2791, "Colesevelam", "", 
99, ObservedResult, 2792, 2801, "increased", "", "<http://ctro/data#Outcome_34866> <http://ctro/data#hasObservedResult> \"increased\". <http://ctro/data#Outcome_34893> <http://ctro/data#hasObservedResult> \"increased\"."
101, EndPointDescription, 2802, 2813, "cholesterol", "", "<http://ctro/data#EndPointDescription_34852> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_34851> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_34852>."
102, EndPointDescription, 2818, 2837, "bile acid synthesis", "", "<http://ctro/data#EndPointDescription_34857> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_34856> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_34857>."
100, ObservedResult, 2842, 2851, "decreased", "", "<http://ctro/data#Outcome_34920> <http://ctro/data#hasObservedResult> \"decreased\"."
103, EndPointDescription, 2852, 2875, "FGF - 19 concentrations", "", "<http://ctro/data#EndPointDescription_34862> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_34861> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_34862>."
208, ObservedResult, 2888, 2897, "no effect", "", 
104, EndPointDescription, 2910, 2948, "fractional hepatic de novo lipogenesis", "", 
79774, Colesevelam, 2982, 2993, "Colesevelam", "", 
108, ConclusionComment, 2982, 3207, "Colesevelam , a non - absorbed bile acid sequestrant , increased circulating incretins and improved tissue glucose metabolism in both the fasting and postprandial states in a manner different from other approved oral agents .", "", "<http://ctro/data#ClinicalTrial_34518> <http://ctro/data#hasConclusionComment> \"Colesevelam , a non - absorbed bile acid sequestrant , increased circulating incretins and improved tissue glucose metabolism in both the fasting and postprandial states in a manner different from other approved oral agents .\"."
107, OralAntidiabeticAgent, 3194, 3205, "oral agents", "", 
109, PMID, 3362, 3370, "22134839", "", "<http://ctro/data#Publication_34511> <http://ctro/data#hasPMID> \"22134839\"."
